Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine

Author's Avatar
Jun 25, 2020
Article's Main Image

Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced the China National Medical Products Administration (or NMPA) issued a product license for its quadrivalent Influenza vaccine (or QIV).